GSK has received approval for its vaccine, AREXVY, in Canada to prevent LRTD caused by RSV in adults aged 50 to 59 years.

A total of 739 deals were completed so far this year representing a decrease of just under 21 per cent compared to last year.

ASHG welcomed eight 2024–2026 Human Genetics Scholars who are recognized for their accomplishments and commitment to fostering DEI in human genetics and genomics.

The patient died four months after BEAM-101 infusion “due to respiratory failure that was determined by the investigator to ...

Scientists at the Johns Hopkins Kimmel Cancer Center have identified 16 genes that breast cancer cells use to survive in the bloodstream after they've escaped the low-oxygen regions of a tumor.

For anyone who wants to understand GSK's profit beyond the statutory numbers, it's important to note that during the last ...

The UK government said on Tuesday it has confirmed a strain of the H5N5 bird flu virus in commercial poultry at a premises ...

This update in the health sector highlights major developments including DiaSorin's significant profit growth, GSK's RSV ...

Heading into Moderna’s third-quarter earnings, investors and analysts will be watching to see how the Cambridge drugmaker ...

Shares of GSK PLC GSK dropped 1.59% to £13.92 Tuesday, on what proved to be an all-around poor trading session for the stock ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

Moderna MRNA is set to report third-quarter 2024 earnings on Nov. 7, before the opening bell. The Zacks Consensus Estimate ...